BeOne Medicines announces voluntary agreement with U.S. Government to expand access to innovative cancer medicines

BeOne Medicines, Ltd., a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S…

Continue ReadingBeOne Medicines announces voluntary agreement with U.S. Government to expand access to innovative cancer medicines

GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?

A narrative review suggests GLP-1-based therapies deliver metabolic, cardiovascular, renal, and other systemic benefits, raising interest in whether lower fractional doses could improve tolerability and treatment continuity. However, direct evidence…

Continue ReadingGLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them?